PARP inhibitors, including olaparib, niraparib, veliparib, rucaparib, and talazoparib, have achieved promising therapeutic outcomes and conferred clinically meaningful benefits to pancreatic cancer patients with BRCA1/2 mutations [24]. This evidence concerns the gene PARP1 and pancreatic neoplasm.